▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #675 by analyst upside · 2026-09-08
EVMN
Evommune, Inc.
Healthcare · Market Cap $445M · P/E 0x
ANALYST PRICE TARGET
+125.1%
implied upside to consensus target
Current Price $12.27
Consensus Target $27.62
Bull Target $32.0
Bear Target $22.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
4
Hold
1
Sell
0
52-Week Low $10.47
52-Week High $33.2
YTD Return -29.1%
FUNDAMENTALS
Market Cap $445M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-11.82
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $10.47
52-Week High $33.2
Current Price $12.27
Bear Target $22.0
Bull Target $32.0
● Now $12.27 ● Target $27.62
TRADING DATA
Avg Volume 795K
YTD Return -29.1%
Analyst Count 8
Consensus Buy
Upside to Target +125.1%
Last Updated 2026-09-08

ANALYST SUMMARY

Evommune, Inc. (EVMN) is currently trading at $12.27 with a Wall Street consensus price target of $27.62, implying potential upside of 125.1% over the next 12 months. 8 analysts currently cover EVMN, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $22.0.

EVMN operates in the Healthcare sector with a market capitalisation of $445M. The stock is down 29.1% year-to-date and is currently trading near the lower end of its 52-week range of $10.47 – $33.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +136.7%
Agenus Inc.
$371M · P/E 2.8x · Buy
CRMD +82.7%
CorMedix Inc.
$657M · P/E 3.9x · Strong Buy
TCMD +78.3%
Tactile Systems Technology, Inc.
$495M · P/E 20.4x · Buy
ZVRA +101.6%
Zevra Therapeutics, Inc.
$736M · P/E 13.3x · Buy
COLL +110.8%
Collegium Pharmaceutical, Inc.
$729M · P/E 18.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EVMN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham ● Initiated
Buy 2026-08-26 20% win rate (5 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-08-03 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-06-30 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-06-30 31% win rate (48 calls)
William Blair ↓ Downgrade
Outperform → Market Perform 2026-06-29 44% win rate (9 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
17/30
Consensus clarity
14/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →